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Abstract
A detailed survey of the current trends and recent advances in rotary mechanical circulatory support systems is pre-
sented in this paper. Rather than clinical reports, the focus is on technological aspects of these rehabilitating devices as a
reference for engineers and biomedical researchers. Existing trends in flow regimes, flow control, and bearing mechan-
isms are summarized. System specifications and applications of the most prominent continuous-flow ventricular assistive
devices are provided. Based on the flow regime, pumps are categorized as axial flow, centrifugal flow, and mixed flow.
Unique characteristics of each system are unveiled through an examination of the structure, bearing mechanism, impeller
design, flow rate, and biocompatibility. A discussion on the current limitations is provided to invite more studies and
further improvements.
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Introduction
Mechanical circulatory support (MCS) is becoming a
realistic alternative to heart transplant for terminal
heart failure, after exhaustion of medical and conven-
tional surgical treatments. Each year, there are more
patients who need long-term cardiac care. Meanwhile,
the number of successful transplants remains stagnant.1
Several modalities exist for providing support to heart-
failure patients as a2:
. Bridge to decision (BTD)
. Bridge to recovery (BTR)
. Bridge to transplant (BTT)
. Destination therapy (DT)
Although each device has its unique characteristics,
most of the available systems can be classified into two
categories: total artificial hearts (TAHs) and ventricular
assistive devices (VADs). TAHs replace a portion or all
of the heart, similar to a prosthesis, with a device that
achieves systole and diastole by filling and emptying
artificial chambers in repetitive cycles. VADs, on the
other hand, are designed to augment the function of a
failing heart as an orthosis without replacing the
biological organ. They can provide support to either
left (LVAD), right (RVAD), or both ventricles
(BiVAD).
Based on the flow regime, VADs can be categorized
as: positive displacement (PD-VADs) or continuous
flow (CF-VADs). In PD-VADs, the pump is connected
to an external driver (pneumatic, hydraulic, or electric)
that provides alternating pressure and vacuum to fill
and empty the pump chambers. CF-VADs generally
provide cardiac support by providing a continuous
output flow that increases the arterial blood flow and
pressure. Angular momentum is generated through
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rotation of a miniaturized impeller that is further con-
verted to linear flow. The speed of rotation has a direct
relation with the output flow rate.
Continuous flow
While PD-VADs maintain the physiological nature of
blood flow, they often have limited lifetime and low
reliability due to mechanical failure in diaphragms
and valves. Today, CF-VADs comprise over 98% of
LVAD implantations in USA,3 as they often lead to
better outcomes.4 They have shown promising results
due to5:
. Lower power consumption
. Lower hemolysis risk
. Lower infection risk
. Lower sound level
. Less hospitalization and equipment cost (in long-
term)
Moreover, these devices are more compact (25 cc vs.
150 cc) that makes them more suitable for patients with
small body-surface area (BSA) and children. The
smaller size makes the thoracic implantation achiev-
able, which is a better site than the usual upper
abdomen.5
LVAD recipients may develop right ventricular fail-
ure during or shortly after device implantation. This is
partly contributed to rapid unloading of the left ven-
tricle, which may cause deviation of the interventricular
septum towards the left ventricle, thus reducing right
ventricular efficiency.6 The very first symptom of right
ventricular dysfunction in these patients is often the
inability of the LVAD to fill the ventricle that leads
to insufficient flow rate. The limited filling is exacer-
bated when the right heart failure is followed by an
elevated transpulmonary pressure gradient or high pul-
monary vascular resistance. Until recently, TAHs were
the only option for severe biventricular failure. Modern
CF-VADs have shown promising results when two
devices are implanted as a BiVAD.7 Patients with
BiVAD will not be as dependent on the MCS as
patients with TAH. Device malfunctions are easier to
manage with a BiVAD compared with a TAH.
Moreover, BiVAD implantation does not eliminate
the possibility of myocardial recovery.
Flow regimes
The overall design of the pump including the flow
regime, bearings, blood-contacting surfaces, and flow
path define the hemolytic and hemodynamic perform-
ance of the device. Three types of continuous-flow
pumps have been proven in providing durable support:
centrifugal flow pump (CFP), axial flow pump (AFP),
and mixed flow pump (MFP).8 In CFPs, the outlet is
positioned tangentially to the pump housing, and rota-
tion of the impeller causes the centrifugal force to suck
the blood from the inlet and pump it through the outlet.
In AFPs, the outlet is co-linear with the rotating sec-
tion, and the impeller blades are shaped to accelerate
the blood both rotationally and axially. An MFP com-
bines both flow types, and impeller blades have a
convex profile shape. The degree of convexity varies
based on the dominant flow model. Figure 1 provides
an example of impeller design and flow regime for each
category.
When normalized to the pump size, CFPs are cap-
able of generating a typical pressure gradient, DP, over
a wide spectrum of flow rates, Q. This is often called
flat head curve.11 In contrast, AFPs have a steep head
curve where there is an almost linear relation between
Q and DP.12 MFPs tend to extend the flat region by
providing high DP at high Q.13 Figure 2 compares pres-
sure–flow relationships of a typical CFP, AFP, and
MFP at the same speed.
The flat head curve means greater sensitivity of the
flow–pressure relationship that results in greater change
in Q for any given DP across the inlet and outlet of the
pump. During a cardiac cycle that the pressure head
Figure 1. Different flow regimes in rotary ventricular assistive
devices (reprinted with permission9,10). (a) Centrifugal flow, (b)
axial flow and (c) mixed flow.
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changes from a min Q at diastole to a max Q in systole
(e.g. 40mmHg to 80mmHg), the pump exhibits larger
change in flow rate (e.g. 0 lpm to 10 lpm), emulating a
pulsatile flow. This greater DQ increases the accuracy of
the estimated flow from pump speed and power.
Flow control
In CFPs, the motor current is used as a sensorless index
of pump flow and a virtual index of the left ventricular
pressures during the cardiac cycle. This is based on the
linear current–flow relationship across the full range of
operating pump flows in these pumps. This information
allows centrifugal pump controllers to monitor the
pump flow and the degree of left ventricle unloading
by simply monitoring the motor current or power.11
The correlation between flow and current in AFPs
and MFPs is not nearly linear over the full operating
flow range of the pump. Therefore, motor current offers
less accuracy for flow estimation. Without a flow
sensor, AFPs often cannot report accurate flow,
especially at low rates.12 For example, the HeartMate
II axial flow pump does not display flows below
3.0 lpm. The HeartAssist 5 (ReliantHeart) uses an
ultrasonic flow probe incorporated in its outlet conduit
to measure the flow rate directly.
Regardless of the algorithm, accurate flow estima-
tion depends on viscosity of patient’s blood.
Currently, only one device (HeartWare HVAD) has
adjustable hematocrit setting for adjusting the blood
viscosity in flow estimations. Variable viscosity and
non-linear relations between flow rate, current, speed,
and power, hinder the automatic control algorithms of
CF-VADs.
Although CF-VADs do not generate pulsation, the
pressure difference between the pump inlet and outlet is
pulsatile since the actual heart is still beating. For some
devices, backflow may happen at lower speeds (less
than 1000 rpm).17 It has also been reported that the
pressure variation can diminish at higher speeds
(more than 10,000 rpm) resulting in a non-pulsatile
flow.17 Some researchers have attempted to vary the
CF-VAD RPMs throughout the cardiac cycle to
achieve some measure of pulsatility.18 The usefulness
of such control algorithms remains to be determined.
Moreover, a CF-VAD is blind to the absolute
pressures at the inlet and outlet ports, and responds
only to the DP. This can lead to inlet cannula suction
if the pump increases DP at low left ventricular volume
(e.g. hypovolemia). As discussed earlier, AFPs (and
MFPs to some extent) have a steep Q–P behavior
that leads to higher inlet suction at lower flow rate.
Higher suction increases the risk of sucking the ven-
tricular wall in around the inlet cannula. This means
that a flow control algorithm should include multiple
parameters, including (but not limited to):
. Pump speed
. Pressure differential
. Blood viscosity
. Absolute inlet pressure
. Absolute outlet pressure
. Vascular and valvular resistances
. Systemic, ventricular, atrial, and aortic compliances
. Inlet, outlet, and pump resistances
. Aortic inertance
. Inlet, outlet, and pump inertances
The controller state variables are left ventricular
pressure, left atrial pressure, arterial pressure, aortic
pressure, total flow, and pump flow.
Bearings
Various bearing mechanisms have been investigated for
supporting miniaturized impellers in CF-VADs.
Summarized below and illustrated in Figure 3 are
those currently in use.
Mechanical pivot bearing. In early versions of CF-VADs,
the rotor was supported mechanically by journal and
thrust bearings.20 These bearings evolved into low-wear
pivot bearings made of precision ceramic components.
Figure 3(a) is the HeartMate II (Thoratec) inlet bearing
ball and cup. This bearing set was explanted from a
pump that was in operation for 4.4 years and
demonstrates low wear.19 Although these bearings are
small, they are potential sites for thrombus and fibrin
deposition, which is not present in other bearing
designs that completely suspend the rotor.12 The con-
centration of hydrodynamic loads on these bearings,
especially at stress concentration points, makes them
theoretically susceptible to wear and fatigue.
Hydrodynamic radial and thrust bearing. One of the biggest
breakthroughs in the development of MCS systems was
the introduction of contactless bearings in 1980s. It was
Figure 2. Typical P–Q results for centrifugal, axial, and mixed
CF-VADs at the same speed.11,14–16
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first achieved by filling the rotor bearing with cross-
linked blood or other biocompatible materials.21,22
Hydrodynamic bearing has been utilized in both
radial and thrust configurations. In either configur-
ation, a fluid film pressure acts to separate the rotating
surfaces from the stationary base. Hydrodynamic bear-
ings provide no life-limiting contact while in motion,
however, surfaces will touch when stationary (start
and end). Moreover, they apply more shear stress on
blood cells especially at the boundary layer. Higher
shear stress increases the risk of hemolysis. An example
of hydrodynamically suspended pump is HeartAsssit 5
(ReliantHeart). In Figure 3(b), the magnitude and
direction of these fluid forces are represented by the
height and direction of the arrows.
Permanent magnet bearing. Using repelling neodymium-
boron-iron magnets on the rotor and housing allows
for suspending the rotor. Permanent magnet bearings
allow for a larger gap between the static motor
armature and the rotor, while eliminating the need for
mechanical bearings, lubrication, sealing, and purging
fluid. However, the magnetic forces are dependent on
the instantaneous position of the rotor. Therefore, the
magnetic bearings are often used in conjunction
with hydrodynamic or electromagnetic bearings. An
example of permanent magnet bearing combined with
hydrodynamic bearing is HeartWare HVAD
(HeartWare International), as illustrated in
Figure 3(c). The rotor is aligned and separated from
the conical stationary center shaft of the pump housing
using magnetic bearing. A thin film of blood generates
pressure at the tapered surface of the impeller (red line)
to create hydrodynamic elevation.12 Stator coils in the
housing are supplied with electric currents having a fre-
quency and amplitude adjusted to the blood pressure at
the pump inlet.23–25
Electromagnetic bearing. Electromagnetic bearings con-
trol three degrees of freedom of the impeller: axial,
radial, and tilt. Either axis can be active or passive. In
active mode, the repelling force is adjusted by changing
the supplied current to the electromagnets based on the
instantaneous position or other feedback errors. In
passive mode, the supplied current to the electromag-
nets is constant. The electromagnetic force adjusts auto-
matically based on the position itself. An example of
electromagnetic suspension is INCOR (Berlin Heart)
(Figure 3(d)). INCOR uses active control for the axial
position, and passive control for radial and tilt.
Electromagnetic bearings eliminate life-limiting contacts
and reduce stress on blood cells at the cost of added
components, electronics, and controllers. If a moment-
ary drop in control signal occurs, pump failure will be
inevitable. Therefore, these bearings are often backed up
with a bearing that does not require active control.
Biocompatibility
The common practice in manufacturing VADs is highly
polished blood-contacting surfaces made of biocompat-
ible materials such as titanium. The sintered titanium
surface may be textured to reduce anticoagulation
requirements and thromboembolism. To decrease the
incidence of thrombus formation, some devices coat
the blood-contacting surfaces with materials that
reduce platelet activation and adhesion. Common coat-
ing materials used in VADs are listed below.
Figure 3. Bearing mechanisms in rotary ventricular assistive
devices (reprinted with permission12,19). (a) Mechanical pivot, (b)
hydrodynamic radial (left) and thrust (right), (c) permanent
magnet (combined with hydrodynamic bearing) and (d)
electromagnetic.
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Carmeda. BioActive Surface is a heparin-based,
thrombo-resistant coating developed for medical
devices in contact with blood. The coating is applied
by stepwise deposition of cationic and anionic polymers
(layer-by-layer) on the device surface, ending with
covalent end-point attachment of heparin, a well-estab-
lished and widely used anticoagulant. What is unique to
Carmeda BioActive Surface is the retained functional
activity of the immobilized heparin, specifically the cap-
acity to bind to the coagulation inhibitor antithrombin
(AT). This natural inhibitor in blood acts by forming a
complex with activated coagulation factors (enzymes),
thereby neutralizing their pro-coagulant activity. The
binding of AT to heparin increases this inhibitory cap-
acity drastically, thus converting AT from a slow to a
highly potent coagulation inhibitor. Inactive complexes
formed on the immobilized heparin are released and
swept away from the surface by the blood flow.
Hence, the end-point attached heparin is not consumed
but remains active and available for further inhibition.
In addition to downregulating the coagulation, the
advantages of the Carmeda BioActive Surface include
platelet compatibility and reduced activation of natural
defense mechanisms.26
Trillium. It is a polymer coating with applied heparin to
the blood-contacting surfaces. A priming layer is
bonded to the blood-contacting surface. A hydrophilic
functional layer with heparin is deposited to the prime
coat and provides the key endothelial-like behavior for
the surface of the ventricular assistive device. This func-
tional level includes three primary elements:
. Non-leaching heparin molecules are covalently
bonded into the surface to act like heparin sulfate
in vascular endothelium.
. Sulfate and sulfonate groups are incorporated into
the Trillium biosurface layer to emulate the negative
charge of the vascular endothelium. These negatively
charged sulphonated polymers repel platelets (that
are also negatively charged)27 and inhibit thrombin
by attaching to AT (similar to heparin).28
. As a third functional layer, polyethylene oxide poly-
mer is deposited on the surface as a hydrophilic mol-
ecule to create an insulating water layer between
blood and artificial surface to resist cell adhesion
and protein deposition.
These layers lead to a reduction in platelet activation
measured by b-TG. With Trillium, a strict anticoagula-
tion protocol should still be followed and routinely
monitored.29
To provide a systematic review on implantable
CF-VADs, eight prominent technologies are categor-
ized based on their flow regimes. A summary of these
devices is given in Table 1. Many other MCS systems
have been introduced since 1930s, which are either now
defunct or remain investigational. A summary of these
devices is provided in Table 2 as a reference. This
review is intended to discuss the devices in Table 1
from an engineering point of view, rather than clinical
reports. A discussion on the current limitations is pro-
vided to invite further developments. Where possible,
expert advice has been sought from the manufacturers
to provide the most accurate and up-to-date
information.
Axial flow devices
HeartAssist 5
HeartAssit 5 (ReliantHeart, Inc., Houston, TX, USA)
is the modern version of DeBakey/NASA VAD that
has been under development since 1988. It consists of
an inflow cannula, stator in the pump housing, flow
straightener, rotor, and diffuser. This electromagnet-
ically driven pump measures 71mm long by 30mm
diameter and weighs 92 g. It pumps blood flow of 5
to 6 lpm at an average speed of 10,000 rpm to a max-
imum of 10 lpm at 12,500 rpm.30 Due to its small size,
HeartAssist 5 may be implanted above the dia-
phragm, so there is no need to create a pocket for
the pump. Much optimization has been done on the
inlet angle, outlet angle, axial and radial clearances of
blades on flow straightener, rotor (impeller and indu-
cer), and diffuser to minimize the risk of hemolysis
and platelet activation. The HeartAssist 5 Pediatric
VAD uses a 140 inflow cannula and a 60mm out-
flow graft for supporting pediatric patients: as young
as four to six years old, BSA larger than 0.7m2 and
smaller than 1.5m2, weight equal or greater than
18 kg. For adults, however, HeartAssist 5 Adult
VAD uses an 115 inflow cannula and 90mm outflow
graft. Figure 4 compares the pediatric and adult
versions.
A plurality of magnets is placed in each impeller
blade that interact with the axially adjusted stator.31
The straightener and impeller are designed such that
they eliminate any area of blood stagnation and prevent
thrombus formation. Moreover, there is almost no gap
between the body of flow straightener and front hub of
the impeller to eliminate flow recirculation zones in
contact with stationary parts, which again may be
thrombogenic.21,32 In addition to the pump, the
LVAD system comprises a controller module, an ultra-
sonic flow probe, batteries, a battery charger, and a
data acquisition system for home or clinical support.
A cable powers the pump percutaneously and sends the
feedback to the HeartAssist 5 Conquest Controller. A
unique feature of this device is continuous flow rate
Hosseinipour et al. 5
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measurement using an ultrasonic flow probe around the
outflow graft (Figure 5).
All blood-contacting surfaces are made of highly
polished titanium. In an attempt to decrease the inci-
dence of thrombus formation, all blood-contacting
surfaces are coated with Carmeda biocompatible
coating. Recently, ReliantHeart designed a remote
monitoring system for HeartAssist 5, called
HeartAssistRemote, which enables healthcare pro-
viders to monitor the pump remotely. So far,
HeartAssist 5 is the only remotely monitored VAD
in the world. The original DeBakey pump showed a
high incidence of thromboembolic events (22%) and
pump thrombosis (11–36%) and higher mortality rate
in BTT (45%).33 A recent study showed that using
device thrombogenicity emulation (DTE) can opti-
mize the device features. Numerical simulations
reported lower stress on platelets and hence lower
platelet activation.34 The pediatric version of
HeartAssist 5 received FDA approval for BTT in
November 2012, and the Conquest Controller had
been given another CE Mark approval earlier in
October 2012. In Europe, HeartAssist 5 achieved
CE mark approval in 2014. An investigational
device exemption (IDE) was granted to HeartAssist
5 in 2014, and clinical trials are in progress.3
HeartMate II
HeartMate II LVAD (Thoratec Corp., Pleasanton, CA,
USA and Texas Heart Institute, Houston, TX, USA) is
a small AFP for full circulatory support to the left heart
failure patients. It is surgically implanted in either pre-
peritoneal or intra-abdominal cavities with its 20mm
inflow conduit attached to the ventricular apex and a
14mm outflow graft connected to the ascending aorta.
It provides 3 to 10 lpm continuous flow at a pump
speed of 6000 to 15,000 rpm. Sufficient flow rate and
hemodynamic pressure are typically achieved at
9000 rpm.30 The pump housing measures 60mm long
and 40mm diameter, approximately the size of a D-Cell
battery, and weighs 375 g.35 The rotor, which is the only
moving part of the pump, contains a magnet and is
powered by an electromagnetic motor to rotate on
blood-lubricated bearings.36 Like the other AFPs,
there is a risk of generating negative intraventricular
pressure and collapsing the ventricle. Therefore, the
position of the inflow cannula and ventricular preload
are important. Figure 6 shows HeartMate II with
sealed grafts, and Figure 3(a) presents a section cut of
the device showing the rotor, magnets, and bearings.
All internal blood-contacting surfaces including rotor,
inlet stator, outlet stator, and thin-walled duct have a
smooth polished titanium surface. The inflow conduit
and outflow graft have a textured microsphere surface,
which is similar to blood-contacting surfaces on the
HeartMate XVE LVAD.
In addition to HeartMate II LVAD implanted inside
the body, HeartMate II Left Ventricular Assist System
(LVAS) comprises the following components out of
body: system monitor, system controller, portable
Figure 4. HeartAssist 5 pump (Courtesy of ReliantHeart, Inc.).
(a) Adult and (b) low body-surface-area (pediatric).
Figure 5. HeartAssist 5 ventricular assist system (Courtesy of
ReliantHeart, Inc.).
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power module, universal battery charger, portable
rechargeable batteries, battery clips, and a percutan-
eous driveline.37 The polyester velour covered driveline
exits the skin and connects the motor to the system
controller, which continuously powers and controls
the whole system. Figure 7 shows an X-ray of a patient
with HeartMate II LVAS. The system may be driven by
the portable batteries or the power module independ-
ently. The controller runs the pump at fixed-speed
mode, and the speed of rotation is determined at the
time of implantation based on hemodynamic needs.
The rechargeable batteries are 14V Li-Ion or 12V
NiMH, and each pair can provide enough energy to
let the patient live tether free for up to 10 h. The
20-foot power cable in the power module makes it pos-
sible to run the system using external AC power source.
The portable power module runs the pump and
powers the controller. It has integrated battery for
emergency support for up to 30min. The system moni-
tor communicates with the system controller and allows
the user to monitor system parameters or change the
operation speed. It also provides an estimation of
output blood flow based on the pump speed and
amount of power being given to the pump. The rela-
tionship between power and flow at any speed is mostly
linear, with the exception of low and high-end regions.
Currently, Thoratec (Pleasanton, CA, USA) and
WiTricity (Watertown, MA, USA) engineers are
developing a fully implantable version of the device
using an optimized transcutaneous energy transmission
system (TETS).35
HeartMate II has been approved in USA and
Europe for BTT (2008) and DT (2010). In 2009, a sem-
inal trial showed better outcomes for HeartMate II
LVAD compared with HeartMate XVE in a cohort
of patients as ill as those in the original REMATCH
trial. HeartMate II LVAD is the most widely used
LVAD in the world with more than 12,969 implant-
ations between 2004 and 2012.3 In 2015, Thoratec,
Inc. announced the 20,000th implantation.
INCOR
INCOR (Berlin Heart GmbH, Berlin, Germany) is a
long-term implantable axial continuous-flow ventricu-
lar assistive device with direct drive and magnetically
levitated rotor. Complete suspension of the rotor with
two electromagnetic bearings at each end eliminates the
need for mechanical bearings, lubrication, sealing, and
purging fluid. INCOR measures 30mm outer diameter
and 114mm long, somehow the longest among axial
flow devices.30 It weighs 200 g mostly contributed to
its magnetic system components. The pump is capable
of providing a maximum flow rate of 5 lpm at rotation
speed between 5000 and 10,000 rpm. In such range, the
pump consumes 2–4 W power against 100mmHg pres-
sure. Silicon inflow cannula delivers blood from left
ventricular apex, and another silicon outflow cannula
is anastomosed onto the ascending aorta. All blood-
contacting surfaces are heparin coated by Carmeda
process.38 A percutaneous cable connects the pump to
Figure 6. HeartMate II pump with sealed grafts (Courtesy of
Thoratec Corp.).
Figure 7. X-Ray of a patient with HeartMate II LVAS (Courtesy
of Thoratec Corp.).
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control unit and battery packs out of the body. Figure 8
shows the latest version of INCOR.
All components of the INCOR system are intercon-
nected with snap-in connectors for easier assembly.
Figure 9 was taken during the insertion of INCOR
inlet cannula into the apex. The pump housing has a
stationary flow straightener at inflow port and a sta-
tionary diffuser at outflow port, each equipped with
magnets and magnetic coils. The flow straightener
and diffuser reduce the spin of blood flow and add to
the pressure gradient across the pump. The impeller has
arrangements of magnets inside it and is enclosed by
the motor stator. Radial and tilting impeller move-
ments are passively controlled. A unique controller
algorithm positions the rotor axially within the titan-
ium housing to create a constant laminar flow. This
controller commands the currents required for impeller
rotation and stabilization. The faster the pump rotates,
the higher pressure gradient it generates across the
pump, leading to a greater tendency of the impeller
displacing from its central position. The required cur-
rent to counterbalance this flow force is the principle
variable of the pump flow controller.39
The first human clinical trial of INCOR started in
2002. Out of 212 cases worldwide, 65 (31%) were
bridged to transplantation, 11 (5%) were bridged to
recovery, and 43 (20%) were still on the device at the
time of publishing the results.40 Blood chemistry found
no trauma or hemolysis, and there were no device-
related mortalities. INCOR has been approved to be
used for BTT and DT in Europe since 2013. Berlin
Heart started clinical trials for INCOR in 2009 under
an FDA IDE approval.
Impella
Impella (Abiomed, Inc., Danvers, MA, USA) is one of
the world’s smallest pumps and technically an expan-
sion of Hemopump (Medtronic, Inc., Minneapolis,
MN) that works based on the principle of
Archimedes screw.41 This miniature device, often
called transvalvular pump, is small enough to be
implanted into the ventricle through the femoral
artery and powered via a flexible cable from an external
(percutaneous) source of energy. Impella is developed
to serve the patients who develop cardiogenic shock,
and standard medical therapy has not been able to con-
trol or recover the complication. It is designed to
restore stable hemodynamics, reduce infarct size, and
protect the myocardium from ischemic damage. An
impeller is levitated magnetically without any mechan-
ical bearing. It is passively centered in the pump casing
via permanent magnets in combination with hydrody-
namically acting driving forces. The lateral centering of
the impeller is also affected by the permanent magnets
cooperating with the external driving magnetic means.
Rotation of the impeller in the outlet area pulls blood
from the inlet cannula into the root of the ascending
aorta. The largest diameter section of the device is
motor housing that resides in the aortic root, integrated
with a cannula portion.42 The small diameter cannula
passes through the aortic valve with the valve leaflets
around it. It should be small enough to minimize the
risk of aortic valve regurgitation. Impella has four ver-
sions: Impella 2.5, Impella 5.0, Impella LD (left direct),
and Impella CP (cardiac power). A brief comparison of
the three versions is given in Table 3.
Impella 2.5 is implanted percutaneously via a 13 Fr
sheath in the femoral artery, then ascending aorta,
across the valve (aortic or tricuspid) and then into the
ventricle.43 Impella CP delivers more flow on the same
platform as Impella 2.5. Impella 5 is inserted
Figure 8. INCOR pump (Courtesy of Berlin Heart GmbH).
Figure 9. Insertion of inlet cannula of INCOR into the left
ventricular apex (Courtesy of Berlin Heart GmbH).
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peripherally into the femoral or axillary artery into the
left ventricle. Impella LD, however, is inserted surgi-
cally directly into the ascending aorta. Figure 10
shows the Impella 2.5 and an illustration of the
implanted device. All devices are controlled with
Impella Console (Abiomed, Inc., Danvers, MA,
USA). On each version, a pressure sensor is used to
monitor catheter position and calculate the flow.44
Purge tubing attached to the pump supplies the pump
bearings with a blood-compatible purge fluid, typically
20% dextrose in water. The increased viscosity of this
cleansing fluid helps to create a pressure barrier against
the blood that the device is exposed to, thereby mini-
mizing thrombus formation.45 A pressure transducer
(CM-Set) measures the purge pressure in the purge
lumen of the catheter. Currently, B. Braun
(Melsungen, Germany) purge pump is a separate unit
in the Impella Console System.
FDA granted 510(k) clearance to Impella 2.5 (2008),
Impella 5 (2009), Impella LD (2009), and Impella CP
(2012) for partial circulatory support up to 6 h in car-
diac procedures not requiring cardiopulmonary bypass.
In 2016, Abiomed, Inc. announced that it has received
FDA Pre-Market Approval (PMA) for the Imeplla
product series. Altogether, Impella family has been uti-
lized to support more than 10,000 patients in USA. In
Europe, Impella family has received CE mark and is
widely used.42
Centrifugal flow devices
HeartWare HVAD
HeartWare HVAD (HeartWare International, Inc.,
Framingham, MA, USA) is a miniaturized centrifugal
flow pump for full circulatory support. Figure 11
approximates the size of HeartWare HVAD.
Although mainly designed for left heart, it has also
been modified for biventricular support.46,47 The impel-
ler is the only moving part of the pump and is sus-
pended using a hybrid suspension mechanism. The
hybrid suspension incorporates passive magnets and
hydrodynamic thrust bearings. A gentle inclination is
created on the upper surface of the impeller blades. As
the impeller rotates, the generated blood flow across
these inclinations creates a permanent gap between
Table 3. Differences between Impella 2.5, Impella 5.0, Impella LD (left direct), and Impella CP (cardiac power).
Version Impella 2.5 Impella 5 Impella LD Impella CP
Catheter 9 Fr 9 Fr 9 Fr 9 Fr
Motor size 12 Fr 21 Fr 21 Fr 14 Fr
Flow rate 2.5 lpm 5 lpm 5 lpm 4 lpm
Support Five days Seven days Seven days Five days
Max speed 51,000 rpm 33,000 rpm 33,000 rpm 51,000 rpm
Guide wire 0.046 260 cm 0.064 260 cm Not Required 0.046 260 cm
Pressure sensor Direct Differential Differential Direct
Figure 10. Impella LVAD (Courtesy of Abiomed, Inc.). (a)
Impella 2.5 and (b) Illustration of the implanted device (pediatric).
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the impeller and housing such that there is no mechan-
ical contact between the impeller and pump housing.
This hybrid suspension provides an effective wearless
operation, which significantly downsizes the pump.
Figure 3(c) shows an internal view of HeartWare
HVAD.
HeartWare HVAD weighs 145 g and measures
50mm diameter and 50 cc displacement volume. The
impeller within the titanium housing rotates in the
range of 2400 to 3200 rpm and is capable of delivering
up to 10 lpm flow rate. Unlike similar devices, it is
designed to be implanted above the diaphragm adjacent
to the heart, thereby eliminating the need for abdom-
inal surgery. The inflow of the pump is taken via an
integrated inflow cannula, which is directly inserted
into the ventricular apex. The pump then propels
blood through an outflow graft, equipped with strain
relief, into patient’s ascending aorta. Figure 12 illus-
trates the implantation of HeartWare HVAD. Two
independent motor stators with separate circuitry are
available in the pumping unit to easily switch between
single and dual stator modes and therefore increase the
device reliability.
A single driveline exits the patient’s body and con-
nects the pump to an external controller and battery
packs. Either two rechargeable batteries or a battery
plus an adapter (AC or DC) may run the controller
and pump. In the latter case, the pump may be plugged
into an AC or DC outlet. One of the batteries runs the
system for 6 h. When depleted (or adapter discon-
nected), the controller switches to the backup battery
and the depleted one should be recharged. In 2012,
HeartWare, Inc., announced its partnership with
DUALIS MedTech GmbH (Seefeld, Germany) to
develop a fully implantable version of HVAD using
transcutaneous energy transmission systems. The
manufacturer is also developing a miniaturized AFP,
with an approximate displacement volume of 15 cc,
called HeartWare MVAD.48 MVAD impeller suspen-
sion is based on the same technology used in HVAD
and rotates in the range of 16,000 to 28,000 rpm within
a titanium cylindrical housing, capable of providing up
to 10 lpm flow rate. Ideally, MVAD will be implanted
without the need for median sternotomy. The outflow
of MVAD is a 10-mm double woven graft anastomosed
to the aorta.
In 2010, the results of the company’s ADVANCE
trial led to approval of HeartWare HVAD as a
BTT.49 Results showed survival to transplant or
ongoing support of 92% after 180 days. HVAD is
more compact than HeartMate II, which enables its
implantation in smaller patients. This pump is designed
for intra-pericardial placement that decreases the risks
of infection or other complications that may be asso-
ciated with intra-abdominal or pre-peritoneal
approaches.7 HeartWare, Inc. is currently conducting
a clinical trial on HeartWare HVAD for DT.
HeartMate III
HeartMate III (Thoratec, Pleasanton, CA) is a continu-
ous flow centrifugal pump with a magnetically levitated
rotor. The pump is designed to be able to mimic the
biological pulsatile flow through rapid changes of the
pump speed. Although not unique to HeartMate III,
this is a highly important feature considering that the
long-term effects of continuous flow devices on organ
Figure 12. Illustration of the HeartWare HVAD system
(Courtesy of HeartWare International, Inc.).
Figure 11. Approximate size of the HeartWare HVAD
(Courtesy of HeartWare International, Inc.).
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perfusion are not well understood yet. HeartMate III
works based on a self-bearing or bearingless electro-
magnetic design to minimize the life-limiting friction
and wear. A recent design of the pump measured
69mm outer diameter by 30mm height and 200 g
weight, which includes the motor, inflow cannula, flex-
ible recovery section, outflow graft, bend relief, and all
connecting hardware (Figure 13). Rotating in the speed
range of 2000 to 5500 rpm with the prime volume of 50
cc, the pump is capable of providing up to 13 lpm flow
rate. The major parts of the pump are50:
. An upper housing that includes the inflow/outflow
cannula and the top half of the volume
. A lower housing that includes the bottom half of the
volume and a cavity for the motor
. A motor that includes drive and levitation functions
in a single magnetic structure
. A rotor that includes an impeller and passive per-
manent magnets
The spinning rotor draws blood into the pumping
chamber along the rotor’s axis and propels it tangen-
tially through an outflow graft aligned perpendicular to
the inflow cannula.51 Motor drive and magnetic levita-
tion coils share the same stator. Thus, no separate
motor or bearing exists. The impeller rotation is
caused by a moving magnetic field generated by the
drive coils.52 The rotation and radial levitation of the
rotor are controlled by a two-axis active control system
and a feedback control loop. The remaining degrees of
freedom (axial and tilting) are controlled passively by
the magnetic support. Inflow cannula of the device is
inserted into the left ventricular apex, and the outflow
graft is anastomosed to the ascending aorta. All blood-
contacting surfaces of the pump are made of titanium
with the exception of polytetrafluoroethylene (PTFE)
washers at joints and woven polyester grafts. Like
other members of the HeartMate family, HeartMate
III incorporates sintered titanium-textured surfaces to
reduce anticoagulation requirements and thrombo-
embolism. Both percutaneous and implantable versions
of the device are under development. For the percutan-
eous version, a single driveline exits skin and connects it
to a belt-mounted driver/controller. Using a pair of
rechargeable batteries, the wearable power transmis-
sion can run the system for up to 6 h.53 The design of
the HeartMate III has been modified several times
during the developmental process. In another modified
version of the pump, the inflow cannula is integrated
into the pump housing and is inserted directly into the
left ventricular apex.52 Using full active control over the
rotor ramp speed, it can also provide an optional near-
physiologic artificial pulse. The Momentum 3 US IDE
clinical trial for HeartMate III is ongoing with more
than 1000 participants to compare the performance of
HeartMate III to that of HeartMate II. In 2015,
Thoratec announced that HeartMate III has met the
primary endpoint of the CE Mark trial. This trial was
a single arm, prospective, multicenter, non-blinded and
non-randomized study. The study involved up to 50
patients at nine sites in Europe, Australia, and
Canada.54 DT and BTT trials for Heartmate III are
currently ongoing.
CentriMag and PediMag
Thoratec CentriMag and PediMag (Thoratec Corp.,
Pleasanton, CA, USA) are a family of extracorporeal
quickly installable devices for short-term left/right or
biventricular use in patients who need cardiopulmonary
support with potentially recoverable heart failure.
CentriMag and PediMag pumps use magnetic levita-
tion to suspend the rotor by eight L-shaped iron
cores.41 Their extracorporeal system comprises the cen-
trifugal pump, an electromagnetic motor, a drive con-
sole, an ultrasonic flow probe, and a tubing circuit.55
To reduce hemolysis, mechanical gaps in the pump are
more than 0.6mm and the pump has no valves, seals, or
moving parts other than the rotor.56 CentriMag is
appropriate for patients larger than 20 kg and is cap-
able of providing up to 9.9 lpm flow rate under normal
physiologic pressure at rotor speed up to 5000 rpm with
a priming volume of 31mL. PediMag is optimized for
pediatric patients around 20 kg and is capable of
1.5 lpm flow rate with a priming volume of 14mL.
Figure 14 shows the Thoratec PediMag (a) and
CentriMag (b). Figure 15 shows the Thoratec
CentriMag installed on the electromagnetic motor.
Both CentriMag and PediMag operate on the same
hardware platform, eliminating the need to have separ-
ate system setups to support adult and pediatric
patients. They can be used as right/left or biventricular
assist devices with cannulation of the left ventricular
apex, left atrium, or right atrium for inflow, and
Figure 13. HeartMate III (Courtesy of Thoratec Corp.).
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aorta or pulmonary artery for outflow.55 In both
pumps, the inlet is on the same axis as the rotor,
while the outlet is directed perpendicular to the inlet,
tangent to the pump circle. The inflow is a 32 Fr wire-
reinforced cannula, whereas the outflow cannula is a 22
Fr straight one.57,58 These pumps are currently used for
stabilizing hemodynamic needs with minimum mechan-
ical failure and blood-related problems such as hemoly-
sis or pump-induced trauma. Figure 16 compares the
implantation of CentriMag with HeartMate II.
FDA granted 510(k) clearance to CentriMag for use
up to 6 h in patients requiring extracorporeal circula-
tory support during cardiac surgery. Investigational
trials are ongoing in an US pivotal trial to demonstrate
safety and effectiveness for periods of support of up to
30 days. Additionally, CentriMag is approved under an
FDA Humanitarian Device Exemption to be used as an
RVAD for periods of support up to 30 days in patients
with cardiogenic shock due to acute right ventricular
failure. In Europe, CentriMag has CE Mark approval
for up to 30 days of support.
Both devices are cleared for clinical use for up to 6 h.
CentriMag is also being evaluated for BRT or BTT
therapy. It is approved for RVAD support for up to
30 days for patients with cardiogenic shock due to right
ventricular failure. In conjunction with CentriMag
Figure 16. Implantation of Thoratec CentriMag versus
HeartMate II (Courtesy of Thoratec Corp.)
Figure 14. Thoratec PediMag and CentriMag BiVADs
(Courtesy of Thoratec Corp.). (a) PediMag and (b) CentriMag.
Figure 15. Thoratec CentriMag installed on the electromag-
netic motor (Courtesy of Thoratec Corp.).
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console and motor, PediMag blood pump is 510(k)
cleared by FDA for support periods of up to 6 h.
Thoratec announced that they have submitted an IDE
to the FDA to begin a U.S. clinical trial examining the
safety and probable benefit of the device for use up to
30 days to support pediatric patients. Outside USA, the
device is branded as PediVAS and has CE Mark
approval for support durations of up to 30 days.
BPX-80 Bio-Pump Plus and BP-50 Bio-Pump
BPX-80 Bio-Pump (Medtronic, Minneapolis, MN,
USA) is a continuous extracorporeal CFP made of
molded polycarbonate for short-term supports. It has
no impeller vane or roller, which is not commonly
found in other centrifugal pumps.59 The constrained-
forced vortex pumping principle is based on a series of
smooth-surfaced rotating cones that pull the blood into
the vortex created by the rotation of cones. As the
blood flows toward the outlet, the vortex energy, gen-
erated by these cones, is transferred to the blood in the
form of pressure and velocity. The smooth vortex cone
design of BPX-80 Bio-Pump has shown greater air
retention compared with impeller-based centrifugal
pumps. Higher air retention means less air passes
through the pump outlet and finally towards the
patient. This pumping principle promotes laminar
flow and improves the blood-handling capabilities.
The pump utilizes a polycarbonate journal bearing to
support the impeller, which may lead to lower durabil-
ity and higher mechanical wear. The pump also com-
prises a double-lip seal design over this precision
bearing. The size of the pump is as follows: cone-
shaped impeller is 79mm diameter, top housing is
50mm high, and the bottom housing is 16mm thick.
BPX-80 Bio-Pump has a priming volume of 86mL,
weight of 200 g, and consumes 8 W power.13 It is cap-
able of providing up to 10 lpm flow rate at rotation
speeds of up to 4500 rpm.59,60 Figure 17 shows the
BPX-80 Bio-Pump Plus and its cutaway section.
To decrease flow recirculation at the outlet opening
and reduce the free plasma hemoglobin, the ellipse-
shaped intersection of the outlet connector and pump
housing is straightened to a nearly vertical line, based
on computational fluid dynamics (CFD) analysis of
shear stress near the opening. In addition to that, the
pump outlet is tapered in order to create a more gentle
blood flow. The pump is available with two biocompat-
ible coatings: Carmeda BioActive Surface (under
license from Carmeda AB, Sweden.) and Trillium
Biosurface (under an agreement with BioInteractions,
Limited, United Kingdom). The BPX-80 Bio-Pump
Plus runs in conjunction with the remote-tethered
Bio-Console 560 drive system that runs the pump
using integrated brushless DC motor, powers
the pump by two 12V lead-acid gel rechargeable bat-
teries, and controls the pump flow rate. It also detects
generated bubbles and measures the blood pressure.
The Bio-Console560 weighs 17.19 kg and measures
31.88 22.38 43.02 cm, providing a limited level of
mobility. Figure 18 shows the Bio-Pump BP-80 and
Bio-Console560.
BP-50 Bio-Pump (Medtronic, Minneapolis, MN,
USA) is similar to BPX-80 Bio-Pump Plus, designed
for pediatric use and patients with special needs. With
a 48mL priming volume, it is capable of providing up to
1.5 lpm flow rate with a maximum speed of 4500 rpm. It
may be controlled by the same controlling units that run
BP-80 Bio-Pump Plus such as Bio-Console 560. Similar
to BP-80, BP-50 is available with Carmeda Bioactive
Surface. Figure 19 shows the BP-50 Bio-Pump and its
particular console called Bio-Console 540.
BPX-80 Bio-Pump Plus is a 510(k) cleared device
since 1985. It is approved to be used in conjunction
with Bio-Console up to 6 h in extracorporeal cardiopul-
monary bypass. BP-50 has also got a 510(k) clearance
Figure 17. BPX-80 LVAD (Courtesy of Medtronic). (a) BPX-80
Bio-Pump Plus and (b) cross section.
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from FDA. BPX-80, BP-50, and BP-Console are all CE
marked in the Europe.
EvaHeart
EvaHeart (Evaheart, Inc., USA, Pittsburgh, PA, USA
developed by Sun Medical Technology Corp., Nagano,
Japan) is an implantable CFP designed for long-term
left ventricular support. It incorporates one water-
lubricated hydrodynamic journal bearing with pure,
sterile water injected into the pump housing from an
external water reservoir in the controller package via
two 2.5mm pipes embedded in the percutaneous drive-
line. The water and blood chambers are separated from
each other by a thin seal called Cool-Seal. The water
lubricates the journal bearing, cools the motor coil and
journal bearing down, and flushes the inner seal faces.
The hydrodynamic journal bearing supports a shaft
that connects the motor to the impeller. The pump
measures 55mm by 64mm with a priming volume of
132mL and weighs 420 g. It is capable of providing up
to 12 lpm flow rate at 2600 rpm against 100mmHg pres-
sure. At flow rates within 5 to 9 lpm, the power con-
sumption of the pump is reported 9 to 10 W.61 To
provide complete bearing wash out during operation,
vanes have an open-faced and swept back shape.2
Sixteen millimeters inflow cannula and outflow graft
are connected to the ventricular apex and ascending
aorta, respectively. They are made of ePTFE or poly-
ester, and all blood-contacting surfaces are coated with
either diamond-like carbon or a proprietary polymer
called MPC.62 Although the pump has a completely
flat pressure–flow curve, the pump output may
become pulsatile. During systole, when the pressure dif-
ference between left ventricle and aorta drops, an
instant high peak flow leads to a higher peak pressure
in the aorta, which is identical to systolic pressure.
During diastole, as the left ventricle-aorta pressure dif-
ference increases, pump flow rate decreases and thus
creates an instant lowest pressure.63 The initial clinical
trial in Japan completed in 2008 after successful
Figure 18. Bio-Pump BP-80 and Bio-Console560 (Courtesy of
Medtronic).
Figure 19. BP-50 LVAD (Courtesy of Medtronic). (a) BP-50
Bio-Pump and (b) Bio-Console 540.
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implantation in 18 patients. The mean support duration
was 2.76 years with a maximum of 6.29 years. Eight
patients were successfully bridged to transplantation
with mean support time of three years. The overall sur-
vival at six months was 89%.64 The device received the
final regulatory approval from the Japanese
Pharmaceuticals and Medical Devices Agency. As of
December 2013, 118 patients have received the device
(80 ongoing). EvaHeart is still limited to investigational
purposes by Federal law in USA. Currently, Evaheart,
Inc. is conducting BTT trials under an FDA-approved
IDE.3
Mixed flow devices
Synergy micro-pump
Synergy Micro-Pump (CircuLite, Inc., Saddle Brook,
NJ, USA) is a miniaturized partial circulatory support
system developed for long-term use in NYHA class
IIIb/early IV patients. It is intended to be implanted
in less ill patients who have symptomatic heart failure,
but BTR is preferred over BTT or DT for them.
Synergy will augment the native ventricle that provides
some flow by itself, but not sufficiently. This allows the
heart to rest and recover, until the appropriate time for
device explantation.2 Synergy is often characterized by
its hybrid or mixed flow that presents both features of
AFPs and CFPs. It combines axial, centrifugal, and
orthogonal flow paths with a single stage impeller
that is driven by an integrated brushless DC motor.
This titanium micro-pump measures 12mm diameter
by 49mm length, the approximate size of an AA bat-
tery. The pump weighs 25 g and has a priming volume
of 1.5mL. Figure 20 approximates the size of Synergy.
This small size allows the device to be implanted surgi-
cally in the subclavicular space, into a pacemaker-like
pocket, through a right upper chest thoracotomy. This
eliminates the need for cardiopulmonary bypass or ster-
notomy and makes the implantation procedure less
invasive. The inflow cannula is made of silicon and
reinforced by NiTi shape memory alloy and is inserted
into the left atrium. The outflow graft is made of PTFE
with an inner diameter of 8mm and thickness of 1mm,
anastomosed to the subclavian artery. A small percu-
taneous lead connects the pump to the external wear-
able controller that weighs around 1 kg. The
rechargeable dual battery pack can run the system for
6 to 8 h. The pump’s rotor is supported by a mechanical
pivot bearing and stabilized by a combination of mag-
netic and hydrodynamic forces. By operating at the
range of 20,000 to 28,000 rpm, the pump is capable of
providing 2 to 4.25 lpm flow rate. Although the small
size and achieved an operational speed of the device are
promising, this lower flow is a concern in increasing the
risk of thrombus formation.65 Synergy received CE
Mark in 2012 and an IDE approval in 2013 for inves-
tigational trials. The device is being supported by an
NIH grant for further developments, system validation,
and clinical evaluation. The manufacturer is planning
to expand the Synergy technology to cover a broader
patient population. Thus, the next-generation of the
Synergy pumps is currently under development. These
modified versions are designed for endovascular
implantation, right heart support, all support, child
support, and infant support. Figure 21 compares the
implantation of these pumps. The endovascular
system will be implanted with the inflow cannula
placed trans-septal into the left atrium from the sub-
clavian vein and the outflow graft anastomosed to the
subclavian artery. Preclinical animal studies of this
device are now completed, and it is approaching clinical
evaluation in Europe. A modified Synergy pump is also
being designed for right heart support or working in
conjunction with the current design as a biventricular
partial circulatory support system.66 Animal studies
and cannula development of this device are in progress.
All-support platform is intended to cover 500,000
patients market with an optimized design of Synergy
for up to 6.0 lpm flow rate. It aims to accommodate
the complete spectrum of a patient’s circulatory sup-
port needs from partial to full. This version has
passed the proof-of-concept step and is awaiting
animal studies to support the design phase and clinical
evaluation. The child support system is also based on
modified Synergy for 1.5 to 3 lpm output with a differ-
ent cannulation. Input cannula will be inserted into the
Figure 20. Approximate size of Synergy Micro-Pump
(Courtesy of CircuLite, Inc.)
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left ventricular apex, while the outflow graft returns
blood to the ascending aorta. The infant support
system, also called Synergy Nano-Pump, is a super
small pump for 0.3 to 1.5 lpm flow and is currently
under development for completing proof-of-concept.
Current limitations
Although the MCS field has improved significantly
over the past three decades, many challenges are still
hindering development of these devices. Stroke remains
prevalent.67 Questions such as optimum time-point for
MCS, careful patient selection criteria, and how to
maximize the biocompatibility of current systems
remain unanswered or under debate. Currently, the
decision regarding when to implant an MCS is based
on published scientific evidence and INTERMACS
values. Ultimately, a decision should be made between
MCS implantation at a later time point with the risk of
rapidly deteriorating heart failure in the meantime, or
earlier MCS with the risk of complications associated
with MCS therapy.68
The following section provides a summary of the
current limitations and challenges, inviting further
improvements and developments.
Device-related issues
Device-related problems such as coagulation disorder,
gastrointestinal bleeding, pump thrombosis, device-
related infection, and cerebrovascular disorders
remain the most critical challenges for MCS systems.68
Hemorrhage at grafts, thromboembolism at stagnant
areas, and hemolysis due to high shearing stress applied
to the red blood cells are the main issues with these
devices. Heat generation is another matter; if
Figure 21. Modified versions of CircuLite MicroPump (Courtesy of CircuLite, Inc.). (a) endovascular system, (b) right heart support,
(c) all-support and (d) child support.
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temperature increases high enough, proteins in the blood
will denature resulting in irreversible blood damage.
Since no valves are employed in these devices, flow
back into the heart could worsen the heart failure. The
bearing systems for blood pumps should be hemocom-
patible, reliable, and durable. Mechanical bearings need
high flow wash out at the junction between the rotating
and stationary parts, which adds to the complexity and
difficulty of maintenance. For immersed bearings, the
viscous friction in the gap between the rotating impellers
and the stationary housing is very high which increases
the risk of blood damage. The disadvantage of
fully magnetically levitated bearings is that they are
highly dependent on the electromagnetic feedback con-
trol. If this connection is lost, the rotor crashes in the
housing.
Pulsatility
Patients supported by continuous flow pumps often
undergo physiological alterations that are not well
understood.7 Adverse clinical outcomes such as aortic
insufficiency, thrombosis, exacerbation of right heart
failure, and bleeding remain a significant problem
after CF-VAD implantation.69 Although the long-
term effects on survival are unclear,70 it has been
shown that the aortic insufficiency associated with
CF-VADs can result in insufficient flow, increased
thrombogenicity, and reduced chance of myocardial
recovery.71,72 Pulsation may allow more physiologic
unloading of the left ventricle by allowing unloading
only during a portion of the cardiac cycle, as opposed
to the full cardiac cycle in current CF-VADs, thus redu-
cing pulmonary hypertension and right heart failure.73
Although some CF-VAD recipients retain some degree
of pulsatility because of the improvements in the
unloaded heart, others can show no significant pulse,
the consequences of which are not clear yet.
Accurate flow control
Accurate flow control on the current CF-VADs for
achieving pulsatility remains a challenge. Speed modu-
lation may offer a potential solution to create pulsatility
and prevent these undesired consequences.45 However,
the performance of the flow control algorithm is highly
dependent of the accuracy and resolution of the flow
measurement. Since direct flow measurement is often
impossible, an estimation algorithm is used to predict
the pump output based on the pump speed and input
power. Accurate, miniaturized, and biocompatible flow
feedback loops are lacking. Heartmate III, currently
under investigation in USA, has shown promising
results for improved flow accuracy and generating
physiologic pulsatility.3
Using two continuous flow pumps for biventricular
support is still facing major challenges. There is no
algorithm yet for adjusting the left and right flows by
automatically and interdependently adjusting the pump
speeds. Therefore, pumps still need two separate con-
trollers. The necessary manual adjustments complicate
the care of patients on BiVAD support.7 The latest ver-
sions of CFPs are devices with magnetically levitated
and hydrodynamic non-contact impeller suspension
systems.74–76
Thrombogenicity
Despite recent advances in MCS development, most
notably the CF-VADs, their long-term use remains lim-
ited by the thrombotic complications. High shear stress
and recirculating flow patterns can lead to platelet acti-
vation. Blood contact with artificial surfaces can also
stimulate blood clotting. A DT trial on HeartMate II in
2009 showed that 11% of patients suffered a stroke
after implantation due to increased shear stress on
blood cells.77 A considerable rate of thromboembolic
complications was also reported for the AbioCor
TAH.78 The non-physiologic flow patterns in CF-
VADs are considered as one of the major contributors
to hemostatic response. Flow patterns along with the
artificial surface determine where thrombi will form, its
size and composition, and whether it will remain local
or it will embolize.79 Valve designs and hemodynamics
also affect the platelet activation.80 CF-VADs are much
smaller than PF-VADs and have smaller gaps between
components of the pump. In older generation PF-
VADs, any thrombus created in the pump could be
dislocated, possibly leading to a stroke. The smaller
size of CF-VADs makes them susceptible to thrombosis
of the entire pump, where the clot stays in the device
and leads to increased hemolysis and device malfunc-
tion.81 Despite aggressive anticoagulant therapy, MCSs
can change the coagulation through activating platelets
by generating non-physiologic pulsatility, eddy forma-
tion, turbulence, or exposure times along platelet tra-
jectories. Development of optimization methods such
as DTE has shed more light on identifying thrombo-
genic regions. This mathematical method combines
CFD with particle tracking and in-silico device model-
ing to determine stress of individual platelets.79 Platelet
activity state (PAS) also facilitates measurement of
thrombogenicity of devices.82 Development and experi-
mental validation of these methods are still an ongoing
challenge. Management protocols for MCSs are usually
institution dependent, with various factors related to
the clinician’s experience. Anticoagulation therapy has
to be individually tailored. Otherwise, patients may not
receive the correct dose of anticoagulant. A significant
variation exists between over-anticoagulation and
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under-anticoagulation in a patient population where
coagulation response to the MCS varies considerably
between individuals. Over-anticoagulation therapy has
often been associated with gastrointestinal bleeding and
intracranial hemorrhage. Common complications due
to under-anticoagulation include pump thrombosis,
hemolysis, and embolic strokes.
Hemolysis
CF-VADs have demonstrated improved survival and
reduced complications compared with PF-VADs.
Nevertheless, a study in 2014 reported 18 out of 100
patients receiving HeartMate II were diagnosed with
hemolysis.83 They concluded that hemolysis is asso-
ciated with very high one-year mortality that is more
than two times greater than that observed for the non-
hemolyzing patients. Treatments involve MCS
exchange or explantation, listing for transplantation,
or intensifying anticoagulation therapies. Besides
thrombus formation inside the device, a few other hem-
olysis risk factors are:
. Increased shear stress on red blood cells due to
device malpositioning, kinking on the outflow
graft/cannula. These cases are often followed by an
abrupt change in the LVAD performance such as
power spike, flow rate, or pulsatility index
. Dehydration of underfilled left ventricle with
increased inlet velocity
. Regurgitant or stenotic valves
. Transfusion-related to immune- and non-immune-
mediated hemolysis
Due to the inherent complexity of patients’
responses to anticoagulant therapies, clinicians may
have to choose between thrombosis, bleeding, or some-
times both.81 Therefore, achieving the optimal anticoa-
gulation therapy remains an ongoing challenge.
Unfortunately, researchers have limited access to data
regarding the prognosis of patients with hemolysis.
More single-center studies on the incident and clinical
outcomes associated with thrombosis, hemolysis,
gastrointestinal bleeding, and infection have been
reported over the last 5 to 10 years.81,83–87
Gastrointestinal bleeding
Multiple reports have been published on the gastro-
intestinal (GI) bleeding in patients who receive
MCS.88–92 In a narrative review in 2013, 20.5% of
LVAD recipients out of 1543 patients developed GI
bleeding.90 This complication has been more pro-
nounced in CF-VADs compared with PF-VADs.
Bleeding can occur throughout the GI tract. Although
the bleeding is usually manageable, the definite bleeding
site remains unidentified. Lack of enough knowledge
about the bleeding site hinders the MCS technology
refinements and improvements. Despite some GI
bleedings are directly related to the device itself,
LVAD replacement is seldom necessary.93 More
research is needed on the etiology of GI bleeding as
well as the proper anticoagulation management before
and after GI bleeding. The role of anticoagulation
acquired von Willebrand syndrome and platelet dys-
function due to altered hemodynamics are not clearly
understood yet.
Infection
Infection occurs in up to 60% of MCS recipients.94,95
MCS-related infections, bacteremia, and fungemia are
common in these patients. Major MCS-related infec-
tions are percutaneous driveline, pump pocket, and
cannula. The percutaneous driveline, particularly at
the exit site, is quite susceptible to infection. Visual
inspection of driveline for diagnosing infections may
be hindered by purulent discharge and surrounding cel-
lulitis. It is reported that even with infection, systemic
signs such as fever, elevated inflammatory markers, or
leukocytosis may not be present.96 Treatment of infec-
tion may require removal of the device, since the entire
device can be susceptible to biofilm formation.97
Cannula and pump infections are among the most ser-
ious MCS-related infections. Infection along the can-
nula or inside the pump can lead to pump failure due to
flow blockage. Besides the differences in the MCS tech-
nologies themselves, heart failure risk score, older age,
diabetes, renal failure, and nutritional status are known
as the additional factors associated with the overall
infection.
CF-VADs have shown less MCS-related infections
compared with PF-VADs due to smaller pump size and
driveline caliber. However, sepsis and non-MCS-related
infections still cause the majority of infections during
the first 90 days of implantation. MCS-related infec-
tions, especially driveline and pump pocket infections,
comprise the majority of infections after 90 days of
implantation.98,99 Although infection complications of
MCS therapy have been described for many years, cur-
rent recommendations for monitoring infection after
MCS implantation are based on observational studies
and expert opinions. Randomized controlled trials for
studying the MCS-related and non-MCS-related infec-
tions after implantation seem essential. An ongoing
effort towards reducing MCS-related infections is real-
ization of TETS. TETS can recharge the batteries wire-
lessly, so patients are neither tethered to a large air
pumping console nor pierced by drivelines and
tubes.100–102
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